344 related articles for article (PubMed ID: 37298116)
1. Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?
Borea F; Franczak MA; Garcia M; Perrino M; Cordua N; Smolenski RT; Peters GJ; Dziadziuszko R; Santoro A; Zucali PA; Giovannetti E
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298116
[TBL] [Abstract][Full Text] [Related]
2. Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.
Christoph DC; Eberhardt WE
Curr Opin Oncol; 2014 Mar; 26(2):171-81. PubMed ID: 24441503
[TBL] [Abstract][Full Text] [Related]
3. [Malignant pleural mesothelioma: 2013 state of the art].
Campbell K; Brosseau S; Reviron-Rabec L; Bergot E; Lechapt E; Levallet G; Zalcman G
Bull Cancer; 2013 Dec; 100(12):1283-93. PubMed ID: 24225007
[TBL] [Abstract][Full Text] [Related]
4. Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
Di Noia V; Vita E; Ferrara M; Strippoli A; Basso M; Schinzari G; Cassano A; Bria E; Barone C; D'Argento E
Curr Treat Options Oncol; 2019 Feb; 20(3):23. PubMed ID: 30790063
[TBL] [Abstract][Full Text] [Related]
5. The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
Wahba NI; Khorshid O; Abo Elkasem F; Bahnassy A; Gaafer R
Asian Pac J Cancer Prev; 2023 Jan; 24(1):195-205. PubMed ID: 36708568
[TBL] [Abstract][Full Text] [Related]
6. Malignant pleural mesothelioma: an update on diagnosis and treatment options.
Kondola S; Manners D; Nowak AK
Ther Adv Respir Dis; 2016 Jun; 10(3):275-88. PubMed ID: 26873306
[TBL] [Abstract][Full Text] [Related]
7. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
10. Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma.
Zhang D; Liang J; Lv Y; Huang X; Guo W
Medicine (Baltimore); 2022 Dec; 101(52):e32459. PubMed ID: 36596035
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
[TBL] [Abstract][Full Text] [Related]
12. Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP.
Dubois F; Bazille C; Levallet J; Maille E; Brosseau S; Madelaine J; Bergot E; Zalcman G; Levallet G
Target Oncol; 2022 Jul; 17(4):407-431. PubMed ID: 35906513
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study.
Nakano T; Kuribayashi K; Kondo M; Morise M; Tada Y; Hirano K; Hayashi M; Tanaka M; Hirabayashi M
Asia Pac J Clin Oncol; 2021 Jun; 17(3):264-272. PubMed ID: 32893992
[TBL] [Abstract][Full Text] [Related]
15. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
[TBL] [Abstract][Full Text] [Related]
16. Novel therapies for malignant pleural mesothelioma.
Scherpereel A; Wallyn F; Albelda SM; Munck C
Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
[TBL] [Abstract][Full Text] [Related]
17. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
Waterhouse DM; Nwokeji ED; Boyd M; Penrod JR; Espirito JL; Robert NJ; Daumont MJ
Future Oncol; 2021 Jul; 17(19):2439-2448. PubMed ID: 33769073
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
Hassan R; Kindler HL; Jahan T; Bazhenova L; Reck M; Thomas A; Pastan I; Parno J; O'Shannessy DJ; Fatato P; Maltzman JD; Wallin BA
Clin Cancer Res; 2014 Dec; 20(23):5927-36. PubMed ID: 25231400
[TBL] [Abstract][Full Text] [Related]
20. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]